Neuropsychological predictors of response to randomized treatment in obsessive-compulsive disorder


Autoria(s): D'Alcante, Carina C.; Diniz, Juliana B.; Fossaluza, Victor; Batistuzzo, Marcelo C.; Lopes, Antonio C.; Shavitt, Roseli G.; Deckersbach, Thilo; Malloy-Diniz, Leandro; Miguel, Euripedes C.; Hoexter, Marcelo Q.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

06/11/2013

06/11/2013

2012

Resumo

Objective: To identify neuropsychological predictors of treatment response to cognitive-behavioral therapy (CBT) and fluoxetine in treatment-naive adults with obsessive-compulsive disorder (OCD). Method: Thirty-eight adult outpatients with OCD underwent neuropsychological assessment, including tasks of intellectual function, executive functioning and visual and verbal memory, before randomization to a 12-week clinical trial of either CBT or fluoxetine. Neuropsychological measures were used to identify predictors of treatment response in OCD. Results: Neuropsychological measures that predicted a better treatment response to either CBT or fluoxetine were higher verbal IQ (Wechsler Abbreviated Scale of Intelligence) (p = 0.008); higher verbal memory on the California Verbal Learning Test (p = 0.710); shorter time to complete part D (Dots) (p<0.001), longer time to complete part W (Words) (p = 0.025) and less errors on part C (Colors) (p<0.001) in the Victoria Stroop Test (VST). Fewer perseverations on the California Verbal Learning Test, a measure of mental flexibility, predicted better response to CBT, but worse response to fluoxetine (p = 0.002). Conclusion: In general, OCD patients with better cognitive and executive abilities at baseline were more prone to respond to either CBT or fluoxetine. Our finding that neuropsychological measures of mental flexibility predicted response to treatment in opposite directions for CBT and fluoxetine suggests that OCD patients with different neuropsychological profiles may respond preferentially to one type of treatment versus the other. Further studies with larger samples of OCD patients are necessary to investigate the heuristic value of such findings in a clinical context. (C) 2012 Elsevier Inc. All rights reserved.

National Council for Scientific and Technological Development (CNPq: Conselho Nacional de Desenvolvimento Cientifico e Tecnologico) [521369/96-7, 475919/2006-8, 481791/2004-3]

Foundation for the Support of Research in the State of Sao Paulo (FAPESP: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo) [05/55628-08, 05/04206-6, 06/61459-7, 06/50273-0, 06/58286-3]

Identificador

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, OXFORD, v. 39, n. 2, pp. 310-317, DEC, 2012

0278-5846

http://www.producao.usp.br/handle/BDPI/41954

10.1016/j.pnpbp2012.07.002

http://dx.doi.org/10.1016/j.pnpbp2012.07.002

Idioma(s)

eng

Publicador

PERGAMON-ELSEVIER SCIENCE LTD

OXFORD

Relação

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Direitos

closedAccess

Copyright PERGAMON-ELSEVIER SCIENCE LTD

Palavras-Chave #COGNITIVE-BEHAVIORAL THERAPY #NEUROPSYCHOLOGY #OBSESSIVE-COMPULSIVE DISORDER #SEROTONIN REUPTAKE INHIBITORS #TREATMENT-NAIVE #SEROTONIN REUPTAKE INHIBITORS #COGNITIVE-BEHAVIORAL THERAPY #CLINICAL-TRIAL #PREFRONTAL CORTEX #NAIVE PATIENTS #IMPAIRMENT #PHARMACOTHERAPY #PERFORMANCE #DIMENSIONS #INVENTORY #CLINICAL NEUROLOGY #NEUROSCIENCES #PHARMACOLOGY & PHARMACY #PSYCHIATRY
Tipo

article

original article

publishedVersion